# Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer

> **NCT01303159** · NA · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 29 (actual)

## Conditions studied

- Cholangiocarcinoma
- Pancreatic Cancer

## Interventions

- **DEVICE:** Endoscopic bipolar radiofrequency probe (ENDOHPB)

## Key facts

- **NCT ID:** NCT01303159
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2014-01-13
- **Final completion:** 2014-01-13
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** EndoHPB probe is FDA approved and considered standard of care
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303159, "Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01303159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*